Lupeng Pharmaceutical closes RMB170m Series A+ round led by Lilly Asia Ventures

2020-06-25
|
Isiah Liu

Lupeng Pharmaceutical closes RMB170m Series A+ round led by Lilly Asia Ventures

Lupeng Pharmaceutical recently completed 170 million yuan in its Series A+ round of financing. This round was led by Lilly Asia Ventures, with participation from existing investors FC Capital, TF Capital and other institutions.


Having participated in Lupeng Pharmaceutical's seed round since its inception, Kaitai Capital continues to inject cash in this round of financing as an existing investor of the company.


Established in June 2018, Lupeng Pharmaceutical is primarily involved in the development of innovative drugs for the treatment of severe diseases such as tumors, hepatitis B, autoimmunity and other diseases that seriously affect human health.


The company’s core pipeline LP-108 (selective BCL-2 inhibitor) has been approved for clinical stage in China and the United States.


Proceeds from this round of financing will be mainly used for the clinical study of LP-108, a selective BCL-2 inhibitor, as well as the development of several subsequent projects.


RELATED ARTICLES

Xbed Xi Hotel receives RMB100 million in financing
2020-11-18
|
Tourism , PEVC

Memoray completes tens of millions of yuan in Series B financing
2020-11-18
|
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

Sier Education closes multi-mln-dollar Pre-A led by Qiming Venture Partners
2020-10-26
|
Education , PEVC

Eugenlight Technologies closes Series A of RMB tens of millions
2020-09-13
|
PEVC , Semiconductor , Electroinic

Dizal Pharma receives US$100 million in Series A financing
2020-08-23
|
PEVC , Biomedical , Biotech , Pharmaceutical

Hanyu Medical closes RMB500m Series D
2020-08-15
|
PEVC , Medical care

ABM Therapeutics closes USD20m Series A+ round led by China Growth Capital
2020-08-09
|
PEVC , Pharmaceutical , Therapeutic

SalusPharma announces the close of a multi-million-yuan Series A
2020-05-14
|
PEVC , Pharmaceutical

Small-molecule innovative drug developer Lynk Pharma secures multi-million-dollar Series A
2020-04-19
|
Pharmaceuticals , PEVC , Medical care
China SDG